On May 7, 2019 FH Advocate, April Donelson, chose to spend her birthday on Capitol Hill, advocating to make familial hypercholesterolemia (FH) a public health priority with Florida and Texas Congressional leaders. April shared “Ryan’s story” to make sure everyone understands the importance … Read More
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor?
The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for these cholesterol-lowering treatments by 60% to $5,850 per year. As we reported in February, the FH Foundation continues … Read More
The FH Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the list price of Praluent in line with Amgen’s PCSK9 inhibitor, Repatha, which was lowered … Read More
Katherine Wilemon, Founder and CEO, Cat Davis Ahmed, Vice President of Policy and Outreach, and several FH Foundation board members participated in a workshop convened by the National Heart Lung and Blood Institute (NHLBI) in November 2018. The goal of the workshop was to develop a multidisciplinary … Read More
Global Call to Action on FH Roundtable
The FH Foundation is thrilled to continue the Global Call to Action on FH initiative during the 2018 World Congress of Cardiology and Cardiovascular Health (WCC) in Dubai, UAE . The World Heart Federation and the FH Foundation will cohost an international roundtable … Read More